UNSPSC 51141597: Tiagabine hydrochloride

This classification denotes an anticonvulsant agent with the molecular formula C20H25NO2S2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DQH6T6D8OY, chemically known as 3-piperidinecarboxylic acid, 1-(4,4-bis(3-methyl-2-thienyl)-3-buten-yl)-, hydrochloride, (r)- but more generally known as tiagabine hydrochloride, which bears US NIH Compound Identifier 91274. European Medicines Agency schedules Tiagabine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15566MIG.

UNSPSC 51141597 Tiagabine hydrochloride, a Commodity code, shows a significant mismatch between its nominal scope and recent state and local procurement activity. The code nominally describes a specific antiepileptic pharmaceutical, but the single recent solicitation in the record—Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026—requests Naloxone and Safe Drug Deactivation Systems, products unrelated to tiagabine. Naloxone is an opioid-overdose reversal agent, and drug deactivation systems are medical waste or hazardous-disposal equipment, neither of which falls within the anticonvulsant pharmaceutical scope the code purports to cover. The procurement does not reflect actual tiagabine purchasing activity by state or local governments.

Seminole County's solicitation requires annual delivery of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to the county's Community Health Building in Sanford, Florida, under a competitive fixed-fee IFB with a two-year initial term and one-year renewal option. Bidders must provide unit costs, comply with drug-free workplace and E-Verify requirements, maintain specified insurance coverage, and accept a three-month probationary termination clause. The opportunity is potentially FEMA-funded and carries federal environmental compliance obligations. The code shows little relevant recent activity aligned with tiagabine procurement; business development professionals evaluating pharmaceutical or anticonvulsant opportunities should verify that state and local purchasing offices are using the correct UNSPSC classification before pursuing activity under this code number.